CHRISTOPHER BUNKA - 07 Jan 2025 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Chris Bunka/
Issuer symbol
LEXX
Transactions as of
07 Jan 2025
Net transactions value
$0
Form type
4
Filing time
10 Jan 2025, 11:52:41 UTC
Previous filing
10 May 2024
Next filing
16 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX Restricted Stock Award Award $0 +100,000 +37% $0.000000 373,543 07 Jan 2025 Direct F1, F2
holding LEXX common shares 273,543 07 Jan 2025 Direct
holding LEXX common shares 254,412 07 Jan 2025 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEXX Warrants 6,667 07 Jan 2025 Common Shares 6,667 $10.50 Private Holding Company
holding LEXX Stock Options 32,667 07 Jan 2025 Common Shares 26,000 $3.00 Direct
holding LEXX Stock Options 56,001 07 Jan 2025 Common Shares 23,334 $3.00 Direct
holding LEXX Stock Options 71,001 07 Jan 2025 Common Shares 15,000 $3.00 Direct
holding LEXX Stock Options 101,001 07 Jan 2025 Common Shares 30,000 $2.91 Direct
holding LEXX Stock Options 131,001 07 Jan 2025 Common Shares 30,000 $1.15 Direct
holding LEXX Stock Options 180,501 07 Jan 2025 Common Shares 49,500 $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Beneficial ownership reflects the aggregate securities held directly.
F2 The closing price on the Issuer's shares on the date of grant was $2.24.